Abstract
Objective
To evaluate perampanel (PER) when used under real-world conditions to treat people with idiopathic generalized epilepsy (IGE) included in the PERMIT study.
Methods
The multinational, retrospective, pooled analysis PERMIT explored the use of PER in people with focal and generalized epilepsy treated in clinical practice across 17 countries. This subgroup analysis included PERMIT participants with IGE. Timepoints for retention and effectiveness measurements were 3, 6, and 12 months (last observation carried forward, defined as ‘last visit’, was also applied to effectiveness). Effectiveness was evaluated by seizure type (total seizures, generalized tonic-clonic seizures [GTCS], myoclonic seizures, absence seizures) and included ≥50% responder rate and seizure freedom rate (defined as no seizures since at least the previous visit). Safety/tolerability was monitored throughout PER treatment and evaluated by documenting the incidence of adverse events (AEs), including psychiatric AEs and those leading to treatment discontinuation.
Results
The Full Analysis Set included 544 people with IGE (51.9% women; mean age, 33.3 years; mean epilepsy duration, 18.1 years). At 3, 6 and 12 months, 92.4%, 85.5% and 77.3% of participants were retained on PER treatment, respectively (Retention Population, n=497). At the last visit, responder and seizure freedom rates were, respectively, 74.2% and 54.6% (total seizures), 81.2% and 61.5% (GTCS), 85.7% and 66.0% (myoclonic seizures), and 90.5% and 81.0% (absence seizures) (Effectiveness Population, n=467). AEs occurred in 42.9% of patients and included irritability (9.6%), dizziness/vertigo (9.2%) and somnolence (6.3%) (Tolerability Population, n=520). Treatment discontinuation due to AEs was 12.4% over 12 months.
Significance
This subgroup analysis of the PERMIT study demonstrated the effectiveness and good tolerability of PER in people with IGE when administered under everyday clinical practice conditions. These findings are in line with clinical trial evidence, supporting PER’s use as broad-spectrum antiseizure medication for the treatment of IGE.
ABR